HIV-1 Vpr activates host CRL4-DCAF1 E3 ligase to degrade histone deacetylase SIRT7.


Journal

Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645

Informations de publication

Date de publication:
01 03 2021
Historique:
received: 15 05 2020
accepted: 12 02 2021
entrez: 2 3 2021
pubmed: 3 3 2021
medline: 23 2 2022
Statut: epublish

Résumé

Vpr is a virion-associated protein that is encoded by lentiviruses and serves to counteract intrinsic immunity factors that restrict infection. HIV-1 Vpr mediates proteasome-dependent degradation of several DNA repair/modification proteins. Mechanistically, Vpr directly recruits cellular targets onto DCAF1, a substrate receptor of Cullin 4 RING E3 ubiquitin ligase (CRL4) for poly-ubiquitination. Further, Vpr can mediate poly-ubiquitination of DCAF1-interacting proteins by the CRL4. Because Vpr-mediated degradation of its known targets can not explain the primary cell-cycle arrest phenotype that Vpr expression induces, we surveyed the literature for DNA-repair-associated proteins that interact with the CRL4-DCAF1. One such protein is SIRT7, a deacetylase of histone 3 that belongs to the Sirtuin family and regulates a wide range of cellular processes. We wondered whether Vpr can mediate degradation of SIRT7 via the CRL4-DCAF1. HEK293T cells were transfected with cocktails of plasmids expressing DCAF1, DDB1, SIRT7 and Vpr. Ectopic and endogeneous levels of SIRT7 were monitered by immunoblotting and protein-protein interactions were assessed by immunoprecipitation. For in vitro reconstitution assays, recombinant CRL4-DCAF1-Vpr complexes and SIRT7 were prepared and poly-ubiqutination of SIRT7 was monitored with immunoblotting. We demonstrate SIRT7 polyubiquitination and degradation upon Vpr expression. Specifically, SIRT7 is shown to interact with the CRL4-DCAF1 complex, and expression of Vpr in HEK293T cells results in SIRT7 degradation, which is partially rescued by CRL inhibitor MNL4924 and proteasome inhibitor MG132. Further, in vitro reconstitution assays show that Vpr induces poly-ubiquitination of SIRT7 by the CRL4-DCAF1. Importantly, we find that Vpr from several different HIV-1 strains, but not HIV-2 strains, mediates SIRT7 poly-ubiquitination in the reconstitution assay and degradation in cells. Finally, we show that SIRT7 degradation by Vpr is independent of the known, distinctive phenotype of Vpr-induced cell cycle arrest at the G2 phase, CONCLUSIONS: Targeting histone deacetylase SIRT7 for degradation is a conserved feature of HIV-1 Vpr. Altogether, our findings reveal that HIV-1 Vpr mediates down-regulation of SIRT7 by a mechanism that does not involve novel target recruitment to the CRL4-DCAF1 but instead involves regulation of the E3 ligase activity.

Sections du résumé

BACKGROUND
Vpr is a virion-associated protein that is encoded by lentiviruses and serves to counteract intrinsic immunity factors that restrict infection. HIV-1 Vpr mediates proteasome-dependent degradation of several DNA repair/modification proteins. Mechanistically, Vpr directly recruits cellular targets onto DCAF1, a substrate receptor of Cullin 4 RING E3 ubiquitin ligase (CRL4) for poly-ubiquitination. Further, Vpr can mediate poly-ubiquitination of DCAF1-interacting proteins by the CRL4. Because Vpr-mediated degradation of its known targets can not explain the primary cell-cycle arrest phenotype that Vpr expression induces, we surveyed the literature for DNA-repair-associated proteins that interact with the CRL4-DCAF1. One such protein is SIRT7, a deacetylase of histone 3 that belongs to the Sirtuin family and regulates a wide range of cellular processes. We wondered whether Vpr can mediate degradation of SIRT7 via the CRL4-DCAF1.
METHODS
HEK293T cells were transfected with cocktails of plasmids expressing DCAF1, DDB1, SIRT7 and Vpr. Ectopic and endogeneous levels of SIRT7 were monitered by immunoblotting and protein-protein interactions were assessed by immunoprecipitation. For in vitro reconstitution assays, recombinant CRL4-DCAF1-Vpr complexes and SIRT7 were prepared and poly-ubiqutination of SIRT7 was monitored with immunoblotting.
RESULTS
We demonstrate SIRT7 polyubiquitination and degradation upon Vpr expression. Specifically, SIRT7 is shown to interact with the CRL4-DCAF1 complex, and expression of Vpr in HEK293T cells results in SIRT7 degradation, which is partially rescued by CRL inhibitor MNL4924 and proteasome inhibitor MG132. Further, in vitro reconstitution assays show that Vpr induces poly-ubiquitination of SIRT7 by the CRL4-DCAF1. Importantly, we find that Vpr from several different HIV-1 strains, but not HIV-2 strains, mediates SIRT7 poly-ubiquitination in the reconstitution assay and degradation in cells. Finally, we show that SIRT7 degradation by Vpr is independent of the known, distinctive phenotype of Vpr-induced cell cycle arrest at the G2 phase, CONCLUSIONS: Targeting histone deacetylase SIRT7 for degradation is a conserved feature of HIV-1 Vpr. Altogether, our findings reveal that HIV-1 Vpr mediates down-regulation of SIRT7 by a mechanism that does not involve novel target recruitment to the CRL4-DCAF1 but instead involves regulation of the E3 ligase activity.

Identifiants

pubmed: 33648539
doi: 10.1186/s12985-021-01514-2
pii: 10.1186/s12985-021-01514-2
pmc: PMC7923639
doi:

Substances chimiques

IL17RB protein, human 0
Receptors, Interleukin-17 0
SIRT7 protein, human 0
vpr Gene Products, Human Immunodeficiency Virus 0
Ubiquitin-Protein Ligases EC 2.3.2.27
DCAF1 protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
Sirtuins EC 3.5.1.-

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

48

Subventions

Organisme : NIGMS NIH HHS
ID : P50 GM082251
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150458
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
ID : R01AI150458
Organisme : NIAID NIH HHS
ID : P50 AI150481
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM116642
Pays : United States

Références

PLoS Pathog. 2014 Jan;10(1):e1003851
pubmed: 24465204
Mol Cell. 2018 Jun 7;70(5):961-970.e5
pubmed: 29883611
Nat Microbiol. 2018 Dec;3(12):1354-1361
pubmed: 30297740
Nat Microbiol. 2018 Aug;3(8):891-897
pubmed: 29891865
Nature. 2015 Sep 17;525(7569):389-393
pubmed: 26287468
J Biol Chem. 2017 Dec 22;292(51):21117-21127
pubmed: 29079575
Nat Struct Mol Biol. 2016 Oct;23(10):933-940
pubmed: 27571178
Cell Metab. 2014 Apr 1;19(4):712-21
pubmed: 24703702
EMBO J. 2016 Jul 15;35(14):1488-503
pubmed: 27225932
J Biol Chem. 2016 Aug 12;291(33):16936-16947
pubmed: 27354282
J Biol Chem. 2016 Feb 5;291(6):2696-711
pubmed: 26679995
Cell Host Microbe. 2015 Apr 8;17(4):489-99
pubmed: 25856754
Clin Cancer Res. 2014 Apr 1;20(7):1741-6
pubmed: 24536059
Cell Rep. 2019 Apr 30;27(5):1579-1596.e7
pubmed: 31042482
Sci Rep. 2016 Aug 23;6:31924
pubmed: 27550312
Cells. 2019 Oct 24;8(11):
pubmed: 31652959
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9568-9577
pubmed: 31019079
Cell Host Microbe. 2008 Jun 12;3(6):388-98
pubmed: 18541215
mBio. 2018 Oct 23;9(5):
pubmed: 30352932
Curr Opin Virol. 2012 Dec;2(6):755-63
pubmed: 23062609
Nature. 2012 Jul 5;487(7405):114-8
pubmed: 22722849
J Biol Chem. 2015 Jul 17;290(29):17935-45
pubmed: 26045556
Transcription. 2017 Mar 15;8(2):67-74
pubmed: 28067587
PLoS Pathog. 2010 Sep 02;6(9):e1001080
pubmed: 20824083
Cell. 2013 Oct 24;155(3):519-29
pubmed: 24243012
Biochem Biophys Res Commun. 2017 Aug 19;490(2):423-428
pubmed: 28623141
Nucleus. 2017 Mar 4;8(2):107-115
pubmed: 28406750
Nature. 2014 Jan 9;505(7482):234-8
pubmed: 24336198
EMBO J. 2016 Jul 15;35(14):1483-5
pubmed: 27302089
FEBS J. 2017 Nov;284(21):3619-3636
pubmed: 28886238
Cancer Cell. 2012 Jun 12;21(6):719-21
pubmed: 22698398
Nature. 2011 May 25;474(7353):654-7
pubmed: 21613998
Nature. 2011 Jun 29;474(7353):658-61
pubmed: 21720370
Virus Genes. 2017 Jun;53(3):329-339
pubmed: 28258391
EMBO J. 1996 Mar 1;15(5):1112-20
pubmed: 8605881

Auteurs

Xiaohong Zhou (X)

Department of Structural Biology and Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Biomedical Science Tower 3, RM 1055, 3501 Fifth Ave., Pittsburgh, PA, 15260, USA.

Christina Monnie (C)

Department of Structural Biology and Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Biomedical Science Tower 3, RM 1055, 3501 Fifth Ave., Pittsburgh, PA, 15260, USA.

Maria DeLucia (M)

Department of Structural Biology and Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Biomedical Science Tower 3, RM 1055, 3501 Fifth Ave., Pittsburgh, PA, 15260, USA.

Jinwoo Ahn (J)

Department of Structural Biology and Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Biomedical Science Tower 3, RM 1055, 3501 Fifth Ave., Pittsburgh, PA, 15260, USA. jia12@pitt.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH